Eureka 💡

Advocating for the development of a definitive cure, vaccine, or treatment for herpes simplex 1 and 2 (HSV)

[Herpes Update @HerpesSupport_H]

👀 Innovative Molecules has announced that the first participant has been dosed in its Phase 2a clinical trial of adibelivir (IM-250), an investigational oral antiviral for recurrent genital herpes.

The trial will evaluate the drug's safety, antiviral activity, impact on viral shedding, and ability to reduce herpes outbreaks. Adibelivir is designed as a next-generation helicase-primase inhibitor, a different approach from standard antivirals like acyclovir and valacyclovir, with the goal of providing more effective suppression of HSV.

This milestone moves the program into later-stage clinical development and represents another encouraging step toward improved treatment options for people living with recurrent genital herpes.

While it's still too early to know how well the drug will perform, Phase 2a results will be important in determining whether adibelivir can offer meaningful advantages over current therapies.

[Herpes Update @HerpesSupport_H]

🚨 Milestone for HSV research.

Innovative Molecules has dosed the first patient in its Phase 2a trial of adibelivir (IM-250), a next-generation oral helicase-primase inhibitor for recurrent genital herpes.

The study will evaluate safety, antiviral activity, viral shedding, and clinical efficacy an important step toward improved HSV treatments. #HSV #Herpes #ClinicalTrials
👇👇
https://t.co/CalUf5fefL

[Susan Rogers @windtreeocean]

We need to talk about the massive stigma around herpes. 🛑

A lot of people think "only certain types of people" get it. The reality? It doesn't discriminate, and it is incredibly common.

Let's look at the actual data:

The Baseline: The WHO estimates that around 67% of the global population under 50 has HSV-1 (usually oral, but a leading cause of genital herpes too), and about 13% have HSV-2 (primarily genital).
Most people who have it don't even know it because they’ve never had a visible outbreak.

If you are sexually active, you have likely been exposed to herpes or have it yourself. It’s not a reflection of your character—it’s just a super common condition that happens to be transmissible.

Let’s drop the shame and start talking about real sexual health.
#cureHSV
@HerpesSupport_H
@HerpesAdvocate

[Herpes Update @HerpesSupport_H]

6/ Every step forward in HSV research brings us closer to better prevention, better treatments, and ultimately a future with fewer infections worldwide.
#HSV #HSV1 #HerpesResearch #VaccineResearch #PublicHealth

[Herpes Update @HerpesSupport_H]

A new modeling study from Weill Cornell Medicine-Qatar and Qatar University suggests that an effective HSV-1 vaccine could prevent tens of millions of infections in the U.S. over the coming decades.

Researchers found that a vaccine with 70% efficacy and long-lasting protection could avert up to 41.8 million HSV-1 infections by 2075 when combined with adolescent catch-up vaccination.

More evidence that investing in HSV vaccine development could have a massive public health impact. #HSV1 #HerpesResearch #Vaccines
https://t.co/NVVLeO1bwl

[Herpes Update @HerpesSupport_H]

New HSV vaccine research: Scientists developed three mRNA vaccine candidates and found that the bivalent gD2-gE1 vaccine produced the strongest protection in mice against genital herpes challenge.

The vaccine triggered robust antibody and T-cell responses, with its effectiveness linked to a stronger Type I interferon (IFN-I) response that boosted adaptive immunity.

While still preclinical, the findings offer valuable insights for the next generation of HSV vaccines. #Herpes #Vaccines #mRNA

[Herpes Update @HerpesSupport_H]

Centralized review is a great step but patients with herpes also need centralized urgency. Millions live with HSV, yet cures and better treatments remain underfunded. Fair science should also mean prioritizing neglected conditions. It’s time to invest in an HSV cure. #HerpesCure #NIH

[Herpes Advocate @HerpesAdvocate]

ICYMI: We hosted Dr. Harvey M. Friedman on April 9 to discuss herpes vaccine development.

🧬 mRNA vaccines targeting multiple proteins
🧪 Strong preclinical results
👩‍🔬 Early human trials show promise

[Herpes Advocate @HerpesAdvocate]

Watch the full talk:
https://t.co/Fz5Y2v3xCZ
#HerpesResearch #HSV2 #STIAwareness

[Herpes Update @HerpesSupport_H]

📣 Sign to accelerate development of IM-250 (Adibelivir) a promising new HSV treatment designed to target latent virus in nerve cells, reduce reactivation, shedding & transmission, and move us closer to a functional cure for herpes, not just symptom suppression. Urgent action needed. ✍️
https://t.co/4ORbeiHR7W

[Susan Rogers @windtreeocean]

Will NIAID please make herpes cure/treatment research a priority? Billions of people are suffering worldwide from oral, genital, ocular, neonatal, and other related herpes infections. New treatments are urgently needed. It's time. Please.
@HerpesSupport_H
@CDCgov
@NIH
@RobertKennedyJc

[Herpes Update @HerpesSupport_H]

📣 @DrTedros
Over 3 billion people live with HSV-1 or HSV-2 worldwide, yet cure research remains underfunded and underprioritized.
We respectfully ask WHO to help accelerate global investment, partnerships, and innovation toward a cure for herpes. Millions are waiting for hope.
#CureHSV #GlobalHealth #EndTheStigma

[Herpes Update @HerpesSupport_H]

Great results. Now please prioritize HSV and share a clear development timeline. Millions are waiting for better treatments. #HSV #CureHSV

[Herpes Advocate @HerpesAdvocate]

Phase 1B data presented by Dr. Grace Wang showed promising reductions in viral shedding and outbreaks for investigational long-acting HSV therapies.

Science is moving — and HSV research continues to progress.

https://t.co/YZCvIubiUu

#Virology
#LongActingTherapies
#Medical

[Herpes Update @HerpesSupport_H]

Rational Vaccines has developed a therapeutic HSV-1/HSV-2 vaccine now available privately in Munich and Honduras. It involves three injections and may take time for benefit to show, but widespread availability isn’t expected soon.
https://t.co/nkD5zL0QiZ

[Herpes Update @HerpesSupport_H]

HSV impacts millions worldwide, yet treatment options remain limited. We urge Gilead to prioritize ABI-1179 and ABI-5366 and share a clear Phase 2 timeline soon. Patients are watching and waiting for progress.

[Eureka 💡 @eurekand]

@GileadSciences Millions suffer in silence from HSV-1 and HSV-2. It’s more than a virus… it’s stigma, isolation, and daily stress. Encouragingly, efforts like the development of new treatments aim to finally bring relief to those living with herpes.

[Herpes Update @HerpesSupport_H]

Pritelivir’s Phase 3 trial in immunocompromised patients with refractory #HSV showed superior lesion healing (~62.7% vs ~34% with standard care) and a good safety profile paving the way for an FDA NDA submission in early 2026.
https://t.co/o0LOghIg1j

[Herpes Update @HerpesSupport_H]

🎯 Israeli scientists at Bar-Ilan Univ. built an AI that deciphers the “control switches” in herpesvirus DNA that determine when the virus wakes from dormancy, helping uncover viral activation mechanics and potential therapeutic targets.
https://t.co/CgWMBHFlV3

[Herpes Update @HerpesSupport_H]

🚨 New HSV treatment breakthrough: AiCuris’ oral drug pritelivir an innovative helicase-primase inhibitor showed positive Phase 3 results, outperforming standard care in healing resistant HSV lesions in immunocompromised patients. Detailed data set to be presented at #TandemMeetings2026. FDA filing expected later in 2026.
https://t.co/AvaBiyOlpy